Atlas Venture Life Science Advisors, LLC Long-Term Concentrated

CIK: 0001917529 · Show all filings

Period: Q2 2024 (← Previous) (Next →)

Filing Date: Aug 9, 2024

Total Value ($000): $949,643 (100.0% shares, 0.0% debt)

Holdings (15)

DYN Dyne Therapeutics, Inc. 29.8%
Value ($000) $283,031 Shares 8,020,136 Est. Cost $13.82 Unrealized +110.3%
KYMR Kymera Therapeutics, Inc. 16.8%
Value ($000) $159,710 Shares 5,350,422 Est. Cost $58.25 Unrealized -40.6%
Third Harmonic Bio, Inc. 14.9%
Value ($000) $141,802 Shares 10,907,859 Est. Cost $18.97 Unrealized
IRON Disc Medicine, Inc. 11.9%
Value ($000) $113,101 Shares 2,509,456 Est. Cost $48.39 Unrealized -29.8%
DAWN Day One Biopharmaceuticals, Inc. 9.3%
Value ($000) $88,609 Shares 6,430,257 Est. Cost $19.68 Unrealized -25.6%
KRRO Korro Bio, Inc. 4.1%
Value ($000) $38,515 Shares 1,137,149 Est. Cost $33.30 Unrealized +65.9%
QTTB Q32 Bio, Inc. 4.0%
Value ($000) $37,553 Shares 2,092,106 Est. Cost $13.78 Unrealized +73.6%
Generation Bio, Co. 2.5%
Value ($000) $23,348 Shares 8,279,484 Est. Cost $7.08 Unrealized
Vigil Neuroscience, Inc. 2.5%
Value ($000) $23,347 Shares 5,836,874 Est. Cost $7.03 Unrealized
REPL Replimune Group, Inc. 2.0%
Value ($000) $18,885 Shares 2,098,300 Est. Cost $29.91 Unrealized -76.7%
Ikena Oncology, Inc. 0.9%
Value ($000) $8,280 Shares 5,018,178 Est. Cost $12.54 Unrealized
TECX Tectonic Therapeutics, Inc. 0.7%
Value ($000) $6,233 Shares 378,447 Est. Cost $15.77 Unrealized 0.0%
DNTH Dianthus Therapeutics, Inc. 0.4%
Value ($000) $3,545 Shares 136,979 Est. Cost $12.62 Unrealized +90.5%
Aerovate Therapeutics, Inc. 0.3%
Value ($000) $2,987 Shares 1,799,232 Est. Cost $11.88 Unrealized
SPRO Spero Therapeutics, Inc. 0.1%
Value ($000) $696 Shares 535,336 Est. Cost $15.88 Unrealized -90.5%